HC Wainwright Issues Pessimistic Forecast for OnKure Therapeutics (NASDAQ:OKUR) Stock Price

OnKure Therapeutics (NASDAQ:OKUR) had its price objective decreased by HC Wainwright from $40.00 to $34.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

OKUR has been the subject of several other research reports. Leerink Partnrs upgraded shares of OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Oppenheimer reduced their price target on shares of OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a research report on Tuesday, March 11th. Finally, Leerink Partners assumed coverage on shares of OnKure Therapeutics in a research report on Thursday, December 5th. They issued an “outperform” rating and a $33.00 target price for the company. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $32.33.

OnKure Therapeutics Trading Up 1.8 %

Shares of NASDAQ:OKUR opened at $5.00 on Tuesday. The stock has a market cap of $67.18 million, a P/E ratio of -0.41 and a beta of 0.28. OnKure Therapeutics has a 52 week low of $4.45 and a 52 week high of $20.00. The company has a 50 day moving average price of $5.54.

OnKure Therapeutics (NASDAQ:OKUR) last issued its quarterly earnings results on Monday, March 10th. The company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.51). As a group, sell-side analysts predict that OnKure Therapeutics will post -4.05 EPS for the current year.

Institutional Investors Weigh In On OnKure Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC acquired a new position in shares of OnKure Therapeutics during the 4th quarter worth $75,000. OMERS ADMINISTRATION Corp acquired a new position in shares of OnKure Therapeutics during the 4th quarter worth $104,000. Walleye Capital LLC acquired a new position in shares of OnKure Therapeutics during the 4th quarter worth $116,000. Two Sigma Advisers LP acquired a new position in shares of OnKure Therapeutics during the 4th quarter worth $122,000. Finally, Shay Capital LLC acquired a new position in shares of OnKure Therapeutics during the 4th quarter worth $129,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.